The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target<7.0%

被引：0
|
作者：
Liebl, A.
Prager, R.
Kaiser, M.
Binz, K.
Gailwitz, B.
机构：
[1] Ctr Diabet & Metabol, Dept Diabet, Bad Heilbrunn, Germany
[2] L Boltzmann Res Inst Metab Dis & Nutr, Dept Diabet, Vienna, Austria
[3] Novo Nordisk Pharm GmbH, Mainz, Germany
[4] Triemli City Hosp, Dept Diabet, Zurich, Switzerland
[5] Univ Tubingen, Dept Diabet, Tubingen, Germany
来源：
DIABETOLOGIA | 2006年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0998
引用
收藏
页码：610 / 611
页数：2
相关论文
共 50 条
  • [41] Switching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study
    Tosaka, Yuka
    Kanazawa, Akio
    Ikeda, Fuki
    Iida, Mayu
    Sato, Junko
    Matsumoto, Kazuhisa
    Uchida, Toyoyoshi
    Tamura, Yoshifumi
    Ogihara, Takeshi
    Mita, Tomoya
    Shimizu, Tomoaki
    Goto, Hiromasa
    Ohmura, Chie
    Fujitani, Yoshio
    Watada, Hirotaka
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
  • [42] Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart
    Vague, P
    Selam, JL
    Skeie, S
    De Leeuw, I
    Elte, JWF
    Haahr, H
    Kristensen, A
    Draeger, E
    DIABETES CARE, 2003, 26 (03) : 590 - 596
  • [43] Predictors of achieving HbA1c <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study
    Valensi, Paul
    Shaban, Joseph
    Benroubi, Marian
    Kawamori, Ryuzo
    Borzi, Vito
    Shah, Siddharth
    Yang Wenying
    Prusty, Vinay
    Hansen, Jes B.
    Gumprecht, Janusz
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (06) : 601 - 609
  • [44] Comparison of the cost-effectiveness for basal-bolus therapy of type-1 diabetes using insulin detemir plus insulin aspart or human insulin-based regimens in the Netherlands
    Valentine, WJ
    Wittrup-Jensen, K
    Palmer, AJ
    Roze, S
    VALUE IN HEALTH, 2005, 8 (03) : 255 - 255
  • [45] Over 75% of patients with type 2 diabetes reached HbA1c <7% by adding biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment
    Raskin, P.
    Braceras, R.
    Schwartz, S.
    Chaykin, L.
    Chu, P. -L.
    Wynne, A.
    DIABETOLOGIA, 2006, 49 : 487 - 487
  • [46] Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs
    Yang, Wenying
    Ersoy, Canan
    Wang, Guixia
    Ye, Shandong
    Liu, Jun
    Miao, Heng
    Asirvatham, Arthur
    Werther, Shanti
    Kadu, Priti
    Chow, Francis
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 150 : 158 - 166
  • [47] Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes
    Bebakar, Wan Mohamaed Wan
    Chaykin, Louis
    Herslov, Malene Lundgren
    Rasmussen, Soren
    DIABETES THERAPY, 2017, 8 (01) : 197 - 205
  • [48] Insulin detemir reduces the risk of hypoglycaemia at all levels of HbA1c compared to NPH insulin in the context of basal-bolus therapy for type 1 diabetes
    Jones, DR
    Kim, H
    Heller, S
    Clauson, P
    DIABETOLOGIA, 2005, 48 : A92 - A93
  • [49] A COMPARISON OF TWICE-DAILY BIPHASIC INSULIN ASPART 70/30 AND ONCE-DAILY INSULIN GLARGINE IN PERSONS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON BASAL INSULIN AND ORAL THERAPY: A RANDOMIZED, OPEN-LABEL STUDY
    Ligthelm, Robert J.
    Gylvin, Titus
    DeLuzio, Tony
    Raskin, Philip
    ENDOCRINE PRACTICE, 2011, 17 (01) : 41 - 50
  • [50] Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart
    Ashwell, SG
    Gebbie, J
    Home, PD
    DIABETES, 2005, 54 : A119 - A119
12345